A narrative review on the application of high-intensity focused ultrasound for the treatment of occlusive and thrombotic arterial disease

Anand Brahmandam, MD,a,b Shin Mei Chan, BS,b,c Alan Dardik, MD, PhD,a,b,d Naiem Nassiri, MD,a,d and Edouard Aboian, MD,a New Haven and West Haven, CT

ABSTRACT

Objectives: High-intensity focused ultrasound (HIFU) is a noninvasive therapeutic modality with a variety of applications. It is approved for the treatment of essential tremors, ablation of prostate, hepatic, breast, and uterine tumors. Although not approved for use in the treatment of atherosclerotic arterial disease, there is a growing body of evidence investigating applications of HIFU. Currently, percutaneous endovascular techniques are predominant for the treatment of arterial pathology; however, there are no endovascular techniques of HIFU available. This study aims to review the state of current evidence for the application of HIFU in atherosclerotic arterial disease.

Methods: All English-language articles evaluating the effect of HIFU on arterial occlusive and thrombotic disease until 2021 were reviewed. Both preclinical and human clinical studies were included. Study parameters such as animal or clinical model and outcomes were reviewed. In addition, details pertaining to settings on the HIFU device used were also reviewed.

Results: In preclinical models, atherosclerotic plaque progression was inhibited by HIFU, through decreases in oxidized low-density lipoprotein cholesterol and increases in macrophage apoptosis. Additionally, HIFU promotes angiogenesis in hindlimb ischemic models by the upregulation of angiogenic and antiapoptotic factors, with increased angiogenesis at higher line densities of HIFU. HIFU also promotes thrombolysis and conversely induces platelet activation at low frequencies and higher intensities. Various clinical studies have attempted to translate some of these properties and demonstrated positive clinical outcomes for arterial recanalization after thrombotic stroke, decreased atherosclerotic plaque burden in carotid arteries, increase in tissue perfusion and a decrease in diameter stenosis in patients with atherosclerotic arterial disease.

Conclusions: In current preclinical and clinical data, the safety and efficacy of HIFU shows great promise in the treatment of atherosclerotic arterial disease. Future focused studies are warranted to guide the refinement of HIFU settings for more widespread adoption of this technology. (JVS–Vascular Science 2022;3:292-305.)

Keywords: Peripheral arterial disease; High-intensity focused ultrasound; Atherosclerosis; Arterial thrombosis

Peripheral arterial disease (PAD) affects more than 200 million people worldwide and 8 to 12 million people in the United States.1-4 Chronic limb-threatening ischemia represents an advanced stage of PAD, associated with a dismal prognosis of approximately 25% mortality and 30% amputation rates at 1 year.1,5 Moreover, the rates of reinterventions after revascularization remain high, ranging from 20% to 60%, owing to various anatomic, medical, and behavioral factors.6-14 Technological advances have introduced various novel minimally invasive therapeutic modalities such as atherectomy devices, drug-eluting stents and balloons, in an attempt for improved vessel patency and decrease the reintervention rate.15 However, these therapeutic modalities remain invasive and require intraarterial manipulation.

High-intensity focused ultrasound (HIFU) is a noninvasive therapeutic modality, that uses nonionizing ultrasonic waves for focused ablation of desired soft tissues, when acoustic windows are available. The earliest reported use of HIFU was by Lynn et al in 1942,16 who designed a focused ultrasound generator, which produced focused heating in paraffin blocks and liver tissue. They demonstrated that high-intensity ultrasound waves could alter the biologic structure of the targeted tissue and posited that these principles could be applied to humans. Around the same time, Fry et al17,18 in the

The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS-Vascular Science policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest. 2666-3503
Copyright © 2022 by the Society for Vascular Surgery. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jvssci.2022.08.001

292
1950s, used HIFU for thermal ablation of various deep brain structures in experimental animal models. This technology, however, did not rapidly develop owing to the inability to precisely target the desired tissue. Since then, advances in medical physics, imaging and engineering principles have culminated in US Food and Drug Administration (FDA) approval of HIFU for use in the treatment of uterine fibroids, adenomyosis, essential tremors, neuropathic pain, ablation of bone metastases, and prostate cancer. Along with approved therapeutic applications, a growing body of evidence has emerged for use of HIFU in occlusive and thrombotic arterial disease. Although endovascular techniques are predominant for the treatment of arterial pathology, there are no endovascular techniques of HIFU available. This review aims to clarify the basic principles of HIFU related to occlusive and thrombotic arterial disease.

**METHODS**

A literature search of all English language articles in Medline, EMBASE, Web of Science, and Cochrane databases up till 2021 was conducted. The search terms used were “high intensity focused ultrasound” and “atherosclerosis” or “peripheral arterial disease” or “arterial thrombosis” and related terms or abbreviations. All abstracts and full text papers were reviewed by two independent reviewers (A.B and S.M.C), and all differences were resolved in consultation with the senior author (E.A). A total of 313 articles were initially identified. After reviewing for relevance, 303 articles were excluded because they did not meet inclusion criteria of being relevant to HIFU and arterial disease. Sixteen studies were snowballed into the final number of studies, using references and additional searching (Fig 1). Thus, 26 total articles were included in this qualitative review (15 preclinical studies and 11 clinical studies, including 2 that encompassed both preclinical and clinical data).

**RESULTS**

**Principles of HIFU**

The therapeutic effect of HIFU relies on two different physical mechanisms—thermal and nonthermal (Fig 2). Both effects are achieved by using a higher intensity, when compared with diagnostic ultrasound imaging (<0.1W/cm²). The thermal effects of tissue ablation, and coagulative necrosis, are achieved with an intensity ranging between 100W/cm² up to 10,000W/cm² when the ultrasound energy is absorbed by the tissue. At these intensities, ultrasound energy absorbed by the desired tissue is converted to heat and results in coagulation necrosis; this process is presumed to be the primary mechanism of action for the FDA-approved uses of HIFU ablation for prostate carcinoma, uterine fibroids, and essential tremor. The nonthermal effects of HIFU are potentiated by cavitation. At high intensities and low frequencies, ultrasound energy transmitted to the tissues leads to the formation of microscopic bubbles, otherwise known as acoustic cavitation. These bubbles oscillate and enlarge, thereby transmitting shear stress to surrounding tissues, resulting in stable cavitation. An alternate form of cavitation, known as inertial cavitation, results from unstable bubble expansion followed by collapse, resulting in damage to the blood vessels and surrounding tissue. The vascular effects of acoustic cavitation can be attributed to several potential mechanisms—microstreaming, jetting, bubble expansion, and compression. An alternate form of cavitation, known as inertial cavitation, results from unstable bubble expansion followed by collapse, resulting in damage to the blood vessels and surrounding tissue. Microstreaming results in shear stress transmission to endothelial cells from oscillating bubbles, whereas jetting results from asymmetric collapse of the bubbles and is potentially responsible for increased vascular permeability.

The generated ultrasound energy can be focused on the desired tissues through various focusing techniques, such as geometric focusing, electronic focusing, or acoustic focusing. Geometric focusing uses a spherical, concave transducer surface, whereas acoustic focusing uses an acoustic lens for beam focusing. In contrast, electronic focusing relies on multiple piezoelectric crystals with varying excitation signals. An important
discrimination is that the latter technique has the ability to displace the focal point without moving the transducer by altering the exciting signal; this technique is known as electronic steering. In addition to the ability to generate and focus ultrasound beams, a HIFU device must also concomitantly be able to monitor the target tissue, under continuous image guidance, with magnetic resonance imaging or ultrasound examination. To achieve this goal, a real-time dual-mode ultrasound array (DMUA) system for simultaneous imaging and therapy has been developed and described.

Comparison of HIFU with other acoustic therapeutic modalities

Currently available acoustic therapeutic modalities for intravascular use include EkoSonic (EKOS) system (Boston Scientific, Malborough, MA) and Shockwave Peripheral Lithoplasty System (Shockwave Medical Inc., Santa Clara, CA). Intravascular delivery of ultrasound has been assessed in prior in vitro and in vivo studies both for thrombus and atherosclerotic plaques. The EkoSonic (EKOS) system, which combines the principles of intravascular deliverance of ultrasound with fibrinolytic pharmacotherapy, changed treatment of thrombotic processes. EKOS is based on the longstanding principle that the mechanical effects of ultrasound allows for disruption of fibrin strands in thrombus, allowing for the increased uptake of fibrinolytic agents. Multiple large-scale studies such as the Ultrasound Accelerated Thrombolysis of Pulmonary Embolism (ULTIMA) trial and the EkoSonic Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (SEATTLE II) trial have demonstrated clinical efficacy of intravascular ultrasonic energy to augment the effect of thrombolytic agents. In arterial thrombosis, a frequency of 2.2 MHz delivered at a low power (2.1 W) has been effectively used in conjunction with thrombolytic agents. Compared with the EKOS catheter system, which is an invasive modality, HIFU is an extracorporeal, noninvasive modality that requires higher ultrasonic energy to compensate for attenuation.
Shockwave therapy is another acoustic modality with recent applications in occlusive atherosclerotic disease and intravascular or extracorporeal modes of delivery. The intravascular application of shockwave therapy was assessed in the Disrupt studies, using the Shockwave Peripheral Lithoplasty System (Shockwave Medical Inc.) and have demonstrated efficacy in treating stenotic, calcified lesions with a favorable safety profile.\textsuperscript{41,42} The most recent Disrupt III study assessed lithoplasty treatment in combination with drug-coated balloons versus standard balloon angioplasty with drug-coated balloons. In patients with claudication or chronic limb-threatening ischemia and moderate or severe calcification, an initial analysis demonstrated promising results, whereby the use of intravascular lithotripsy was effective at treating stenotic lesions with low rates of complications.\textsuperscript{43} Extracorporeal shockwave therapy for PAD is also being investigated as a noninvasive therapeutic modality, although data remain limited. The principles of shockwave therapy are multifactorial and may include effects on the growth and differentiation of vasculature, nitric oxide synthesis, and macrocirculation.\textsuperscript{44} In murine models, shockwave therapy can induce vascular endothelial growth factor receptor 2 and hypoxia-inducible factor-1 alpha, overall allowing for increased angiogenesis.\textsuperscript{45,46} It has further been suggested that shockwave therapy can mobilize endothelial progenitor cells to promote vasculogenesis.\textsuperscript{46} In multiple small human cohorts, low-energy, extracorporeal shockwave therapy has been shown to decrease arterial stenoses, improve microcirculation in limbs, and improve pain-free walking distance and pain severity scores.\textsuperscript{47-49}

Translational data for applications in arterial disease

Owing to promising results from other applications of HIFU, the impact of HIFU on the progression of atherosclerosis, ability to assist targeted drug delivery for stenotic arterial lesions and sonothrombolysis for acute arterial thromboses are being investigated. Several in vivo and in vitro studies have elucidated the various potential mechanisms of HIFU in atherosclerotic arterial disease (Table I).

Molecular effects of HIFU on atherosclerotic plaque.

Intimal retention of lipoproteins, macrophage compensation of lipids, the formation of foam cells and subsequent cell death are critical processes in the progression of atherosclerosis. These steps center around the role of macrophages, thus, intuitively, strategies targeting macrophages can arrest progression or reverse atherosclerotic plaques. To assess the effects of therapeutic ultrasound on macrophages and atherosclerotic plaque in an atherosclerotic mouse model, Wang et al\textsuperscript{50} used ultrasound beams at a lower intensity (0.4 W/cm\textsuperscript{2}) administered via a 3.5-cm probe with a 1.0-MHz resonance frequency and a duty factor of 10%. They noted that administration of sonodynamic therapy significantly decreased oxidized low-density lipoprotein cholesterol induced macrophage impairment through a heme oxygenase-1. This process resulted in the inhibition of atherosclerotic plaque progression and increased stability of the plaque.\textsuperscript{52} To further this effort, Sun et al\textsuperscript{53} evaluated the efficacy of sonodynamic therapy on atherosclerotic burden in atherosclerotic rabbit and apoE-deficient mouse models. The atherosclerotic rabbits were treated with an intensity of 1.5 W/cm\textsuperscript{2}, and the mice were treated with 0.8 W/cm\textsuperscript{2}. In comparison with the nontreated animals, there was a significant inhibition of atherosclerotic progression as evidenced by approximately 39% increase in fractional flow reserve and a 26% increase in the mean luminal area. Additionally, in the animals treated with sonodynamic therapy there was a decrease in macrophages and lipid content within the plaque, as well as a decrease in intraplaque hemorrhage and increase in the fibrous cap. Importantly, the authors demonstrated sonodynamic therapy induced macrophage apoptosis through a mitochondrial-caspase pathway. The effect of sonodynamic therapy on neo-intimal hyperplasia re-endothelialization in a rabbit femoral artery balloon denudation model was evaluated by another group.\textsuperscript{56} Their histopathological analysis revealed that sonodynamic therapy inhibited neointima formation without impacting re-endothelialization, decreased the content of macrophages, proliferating smooth muscle cells, and collagen without impacting elastin. In vitro, they noted that therapeutic ultrasound induced macrophage apoptosis and decreased interleukin-6, interleukin-1, and tumor necrosis factor alpha via the reactive oxygen species-peroxisome proliferator-activated receptor-γ-nuclear factor-κB signaling pathway. These data show that there are various mechanisms, such as altering plaque lipid content, stabilization of plaque, and induction of macrophage apoptosis, through which HIFU inhibits the progression of atherosclerotic disease.

Effects of HIFU on hindlimb ischemia models.

The various potential molecular responses to therapeutic ultrasound in inhibiting pathways of atherosclerosis, promoting angiogenesis, and limb perfusion are not completely established. Lu et al\textsuperscript{51} studied the effect of ultrasound therapy in a murine hindlimb ischemia model. After surgical induction of hindlimb ischemia, skeletal muscle groups in the mice were treated with lower intensity ultrasound beams of 0.3 W/cm\textsuperscript{2}, through a 2-cm transducer, with a 1.0-MHz resonance frequency for 9 minutes per day for 14 days. Based on thermal infrared imaging analysis, they noted that therapeutic ultrasound normalized lower limb blood flow in diabetic mice with hindlimb ischemia. Immunofluorescence staining showed that capillary density was augmented in these mice. Importantly, they demonstrated that therapeutic ultrasound upregulated angiogenic factors and antiapoptotic factors, while downregulating apoptotic...
| Author(s)         | Year | Model                        | Device name                                                                 | Proposed mechanism of action                                                                 | Available specs | Clinical application                                                                 |
|------------------|------|------------------------------|-----------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|-----------------|--------------------------------------------------------------------------------------|
| **Shehata et al** | 2013 | Swine                        | Imasonic Dual-Mode US Array (Voray sur l’Ognon, France)                     | Thermal Frequency: 3.5 MHz, 64-element phased array transducer with fenestrations, through which 10 MHz transducer is applied. Intensity: 4100-5600 W/cm². Pulse length: 250-2000 ms. |                 | Disruption of atherosclerosis in swine PAD model, accompanied by aggregates of lipid laden macrophages with necrosis. No endothelial damage was noted. |
| **Nazer et al**   | 2015 | Sprague Dawley rats (PAD)    | Duolith SD1 (Storz Medical, Tagerwilen, Switzerland)                       | Biomechanical Frequency: 1.054 MHz. Intensity: 0.1 mJ/mm². |                 | Increase in angiogenesis in hindlimb ischemia model for PAD.                           |
| **Lu et al**      | 2016 | Diabetic C57BL/6J mice       | Custom transducer (Institute of Acoustics of Tongji University, Shanghai, China) | Biomechanical Frequency: 1 MHz. Intensity: 0.3 W/cm². |                 | Increased perfusion in hindlimb ischemia model for PAD accompanied by increased angiogenic factors, antiapoptotic factors, capillary density. |
| **Wang et al**    | 2017 | ApoE−/− mice                 | Custom transducer (Harbin Institute of Technology, Harbin, China)           | Biomechanical Frequency: 1 MHz. Intensity: 0.1-0.4 W/cm². |                 | Inhibition of atherosclerosis via reduction of LDL oxidation.                        |
| **Sun et al**     | 2019 | New Zealand white rabbits, ApoE−/− mice | Custom transducer (Harbin Institute of Technology, Harbin, China) | Biomechanical Frequency: 1 MHz. Intensity: 1.5 W/cm² (rabbits), 0.8 W/cm² (mice). |                 | Decrease in atherosclerosis in femoral arteries through decrease in macrophages and lipids. |
| **Groen et al**   | 2020 | Swine                        | HiFUS Synthesizer, International Cardio Corporation (Edina, MN)           | Thermal Frequency: 3.5 MHz, 64-element phased array transducer with fenestrations, through which 10 MHz transducer is applied. Intensity: 6250 W/cm². |                 | Successful targeting of dorsal wall of the external femoral artery without endothelial damage or complications, accompanied by formation of scar tissue. |
| **Mason et al**   | 2020 | C57BL/6 mice                 | EPIQ 7 (Philips Healthcare, Andover, MA)                                 | Biomechanical Frequency: 1.3 MHz. |                 | Increased perfusion in hindlimb ischemia model for PAD via microcavitation-dependent mechanism. |
Table I. Continued.

| Author(s)       | Year | Model                  | Device name                                                                 | Proposed mechanism of action | Available specs                                                | Clinical application                                                                 |
|-----------------|------|------------------------|------------------------------------------------------------------------------|------------------------------|----------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Yao et al56      | 2020 | New Zealand white rabbits | Custom transducer (Harbin Institute of Technology, Harbin, China)             | Biomechanical               | Frequency: 1 MHz  
Intensity: 1.5 W/cm² (rabbits)                                      | Decrease in carotid artery atherosclerosis through decreased neointima formation, macrophage content, proliferation SMCs, and collagen |
| Francis et al36  | 1995 | Blood samples from adult humans | Custom apparatus made with piezoelectric transducer (manufacturer not specified) | Biomechanical               | Frequency: 1 MHz  
Intensity: 1 W/cm²                                                   | Enhanced thrombolysis via increased uptake of tPA with application of ultrasound     |
| Poliachik et al57 | 1999 | Blood samples from adult humans | Sonic Concepts (Sonic Concepts Inc., Bothell, WA)                             | Biomechanical               | Frequency: 11 MHz  
Intensity: 560-2360 W/cm²                                             | Cavitation and hemolysis is greater in samples with contrast agent treated with ultrasound, versus without |
| Birnbaum et al58 | 2001 | Blood samples from adult humans | Sonicator model XL 2020 (Misonix Inc., Farmingdale, NY)                      | Biomechanical               | Frequency: 20 kHz                                                  | Ultrasound and nongas-filled particles (HAEMACCEL and HAES) decreased clot burden    |
| Hölscher et al59 | 2012 | New Zealand white rabbits | ExAblate 4000 (Insightec Inc., Tirit Carmel, Israel)                         | Biomechanical               | Frequency 220 kHz  
Intensity: 66-200 W (arterial thrombus model), 100-500 W (venous thrombus model)  
Pulse length: 100-200 ms (arterial thrombus model), 0.1-100.0 ms (venous thrombus model) | Mild recanalization in carotid artery stroke thrombosis model, dependent on platelet-activation and cavitation |
| Wright et al60   | 2012 | New Zealand white rabbits | Custom using function generator (model AFG 3102, Tektronix, Beaverton, OR) and amplifier (model A-500, ENI, Rochester, NY) | Biomechanical               | Frequency: 1.51 MHz  
Intensity: 300 W  
Pulse length: 0.1-10.0 ms                                      | Increased thrombolysis and partial blood flow restoration in femoral artery clot model, accompanied by cavitation |

(Continued on next page)
factors. In addition, in an in vitro evaluation of human umbilical vein endothelial cells, therapeutic ultrasound inhibited apoptosis and increased angiogenic factors. Importantly, these effects were blocked by phosphoinositide 3-kinase (PI3K) or endothelial nitric oxide synthase (eNOS) inhibitors, suggesting that therapeutic ultrasound restores angiogenesis through a PI3K-Akt-eNOS pathway. In a similar study, the acoustic effects of shockwave therapy were used and compared with HIFU in an ischemic hindlimb rat model, to evaluate angiogenic effects.\textsuperscript{50} Therapeutic ultrasound was administered three times a week for 2 weeks to the ischemic limbs, at an intensity of 0.1 mJ/mm\textsuperscript{2}, with a resonance frequency of 1.05 MHz through a transducer focused to 63 mm. At the 2-week mark, approximately 60\% improvement was noted in the ischemic limbs, and this

| Author(s)          | Year | Model                     | Proposed mechanism of action                      | Available specs                     | Clinical application                                      |
|--------------------|------|---------------------------|---------------------------------------------------|-------------------------------------|----------------------------------------------------------|
| Damianou et al\textsuperscript{61} | 2014 | New Zealand white rabbits | Biomechanical                                     | Frequency: 1 MHz                     | Enhanced thrombolysis in rabbit carotid model via increased uptake of tPA with application of ultrasound |
|                    |      | Custom device with amplifier (JJ&A Instruments, Duvall, WA) and piezoelectric ceramic transducer (Piezo-technologies, Etalon, Lebanon, IN) | Intensity: 10-40 W/cm\textsuperscript{2}                      |                                     |                                                          |
| Williams et al\textsuperscript{62} | 1978 | Blood samples from adult humans | Biomechanical                                     | Frequency: 0.75, 1.5, 3.0 MHz        | Release of β-thromboglobulin in platelets is mediated by ultrasound-induced cavitation and release of other aggregating factors |
| Vaezy et al\textsuperscript{63} | 1999 | Swine                     | Thermal                                           | Frequency: 3.5 MHz                   | Control of arterial hemorrhage                            |
| Zderic et al\textsuperscript{64} | 2006 | New Zealand white rabbits | Thermal                                           | Frequency: 3.5 MHz                   | Control of arterial hemorrhage                            |
| Lei et al\textsuperscript{65} | 2021 | N/A                       | Thermal                                           | Frequency: 1.1 MHz Power: 15 W at 20 s| Mathematical model to predict damage of plaque ablation based on wall thickness; thermal effects depend on frequency and power |

Table I. Continued.

LDL, Low-density lipoprotein cholesterol; PAD, peripheral artery disease; tPA, tissue plasminogen activator.
was comparable between the shockwave and therapeutic ultrasound groups. Additionally, they noted an increase in microvascular density with therapeutic ultrasound and shockwave therapy. Interestingly, a three-fold increase in tissue vascular endothelial growth factor was observed only in the HIFU group. These data highlight the angiogenic potential of HIFU paving the way for clinical translation in PAD.

Another pathway impacted by therapeutic ultrasound through inertial cavitation, is thought to be mediated through adenosine triphosphate-related purinergic signaling. Mason et al35 used a matrix array transducer with a mechanical index of 1.3, at 1.3 MHz, generating 5-cycle or 40-cycle sinusoidal pulses, or a power Doppler cycle comprising eight 5-cycle pulses with a PRF of 10 kHz. In addition to a variable pulse duration, they also modified the line density, producing sectors of 17, 33, or 65 lines. Lipid microbubbles were injected into 50 mice, after which the mice hindlimbs were exposed to 10 minutes of HIFU. Spatial assessments in this study demonstrated that the higher line densities produced a more rapid and larger areas of inertial cavitation. Contrast enhanced ultrasound revealed a three- to four-fold increase in limb perfusion at higher line densities, and optical imaging showed that both high line density and longer pulse durations resulted in the most adenosine triphosphate release.

Transcutaneous applications of HIFU on atherosclerotic plaque. The role of therapeutic ultrasound in targeting atherosclerotic plaques for treatment by using the thermal effects of HIFU, has also been studied. Shehata et al54 targeted swine femoral arterial atherosclerotic plaques with a DMUA system. The DMUA system included a 10-MHz diagnostic transducer and a 3.5-MHz, 64-element phased-array transducer with a focal length of 40 mm. They subjected four swine to HIFU intensities ranging between 4100 and 5600 W/cm² for durations ranging between 250 and 2000 ms. Histopathological evaluation revealed that the areas of HIFU treatment contained aggregates of lipid-laden macrophages, with condensed basophilic nuclei, suggesting coagulative necrosis. Importantly, the corresponding endothelial lining was preserved, and no arterial rupture, dissection, or perforation was noted. Of note, one animal among the four was noted to have minimal mural thrombus without disruption of the endothelium at a nontreated segment and thrombosis of normal vasa vasora of the treated segment. In contrast with other systems, the DMUA system provides the inherent ability to seamlessly transition between the diagnostic imaging system and therapeutic mode. The presence of a real-time imaging mode, known as single-transmit focus, provides the ability to monitor tissue response before, during, and after HIFU shots. In a similar preclinical study, the effects of robot assisted DMUA HIFU on healthy femoral arteries of 18 swine was studied.55 At 3 and 14 days, there was no endothelial damage, and no significant decrease in arterial diameter. Histopathological evaluation at 14 days showed accumulation of activated fibroblasts and collagen deposition, suggesting scar formation. One animal, intentionally exposed to more than 100 HIFU shots was noted to have heat-induced skin blistering corresponding with the site of application of the HIFU probe. The in vivo safety profile was evaluated in study by Rosenschein et al55 where histologic demonstrated selective disruption of ultrasound-sensitive plaques and thrombi, with minimal damage to healthy arterial wall. These data highlight the importance of combined high-resolution imaging and treatment ultrasound systems such as DMUA probes, to observe and evaluate the effects of therapy in real time.

Transcutaneous application of HIFU on arterial thrombus. An additional effect of therapeutic ultrasound is potentiating thrombolysis, in conjunction with pharmacologic agents, or as a stand-alone modality. The effect of HIFU (1.51-MHz transducer, acoustic power = 300W, pulse length = 0.1-10.0 ms) was evaluated in a rabbit femoral artery thrombus in vivo model and found that 1-ms HIFU pulses resulted in partial flow restoration. Interestingly 10-ms HIFU pulses resulted in substantial bleeding from the femoral arteries.60 The thrombolytic effects of HIFU were evaluated in an in vivo model of rabbit carotid arteries by using the ExAblate 4000 system (InSightec Inc., Tirat Carmel, Israel).59 For the arterial model of thrombus, the authors used acoustic powers ranging between 66 and 200 W, at a 5% duty cycle and a pulse width of 100 to 200 ms. In contrast, the venous thrombus model was subject to acoustic powers between 100 and 500 W and a pulse width of 0.1 to 100.0 ms. In this study, only 9% recanalization was achieved. One possible explanation of this effect is platelet activation induced by HIFU. Williams et al62 showed that the lower therapeutic intensities of HIFU induced platelet activation, as evidenced by release of platelet-specific beta-thromboglobulin. In addition, they also noted increasing levels of beta-thromboglobulin with increasing intensity of HIFU. Interestingly, it has also been reported that lower frequencies (0.75-1.50 MHz) and higher intensities (3.4-4.5 W/cm²) counterbalance the thrombolytic potential, by induction of platelet-activation through inertial cavitation.59,62,66 Interestingly, when human clot was subjected in vitro to therapeutic ultrasound and nongas microparticles, there was a significantly higher percent reduction of the clot.66 In a similar in vitro model, human whole blood samples with and without microbubble contrast agents were subjected to 1.1-MHz ultrasound, at intensities ranging between 560 and 2360 W/cm², resulting in a significant rate of hemolysis.97 The authors reported a 6- to 10-fold increase in cavitation and hemolysis with increasing quantities of microbubbles and increasing intensity of HIFU. This finding suggests a mechanical effect related
to ultrasound-induced microstreaming resulting in a shear stress that augments clot disruption, related to inertial cavitation. In an in vitro model, a group of investigators studied the effect of therapeutic insonation on distribution of tissue plasminogen activator (tPA) using a 1-MHz therapeutic ultrasound at 1 W/cm². They determined that the rate of tPA uptake was significantly faster when subjected to insonation. In addition, the use of radiolabeled tPA demonstrated significantly deeper penetration of tPA, upon exposure to ultrasound. Damianou et al evaluated the combined effect of magnetic resonance imaging-guided focused ultrasound (MRgFUS) and recombinant tPA on thrombolysis in a rabbit carotid model using a 5-cm spherical transducer, capable of focusing at 10 cm, operating at a frequency of 1 MHz and at intensities ranging from 10 to 40 W/cm². They noted a decrease in time to carotid artery recanalization with increasing MRgFUS intensity and noted that, beyond an intensity of 20 W/cm², there was significant heating of the focused tissue. These data suggest a clear augmentation of the pharmacologic effects of tPA in clot disruption. Conversely, HIFU has been evaluated as a tool for hemorrhage control in animal models. In a porcine model, Vaezy et al used a 3.5-MHz HIFU...
transducer with a focal length of 5.5 cm, diameter of 3.5 cm and intensity of 2500 to 3100 W/cm² in femoral and carotid arteries, achieving hemostasis in 46 ± 15 seconds and 31 ± 15 seconds, respectively. Another group used a HIFU applicator of 9.6 MHz with a focal length of 2.5 cm and diameter of 1.9 cm in New Zealand White rabbits for hemostasis in femoral arteries. These animals were studied for 60 days after HIFU exposure. The intensity of this HIFU system was 3000 ± 100 W/cm² requiring a mean HIFU-exposure time of 47 ± 41 seconds. These data support the safety and feasibility of acoustic technology to aid in control of hemorrhage. However, ambiguity regarding the exact HIFU settings, the ability to precisely focus the acoustic beams and the lack of data regarding the long-term molecular effects on endothelial homeostasis of this modality currently limit its use for hemorrhage control.

In total, there is robust preclinical data elucidating the various mechanisms of HIFU in atherosclerotic arterial disease. Notably, HIFU stabilizes atherosclerotic plaque and inhibits plaque progression through macrophage apoptosis potentially mediated through a reactive oxygen species-peroxisome proliferator-activated receptor-γ-nuclear factor-kB pathway. Interestingly, HIFU inhibits

| Device name | Route of application: proposed mechanism of action | Available specs | Clinical relevance |
|-------------|---------------------------------------------------|-----------------|-------------------|
| Ultrasound Angioplasty Ablation System (Baxter Edwards LIS Healthcare Corporation, Bentley Laboratories, Europe BV) | Invasive; biomechanical | Frequency: 19.5kHz Intensity: 115-V electrical generator | 86% lesions recanalized with ultrasound |
| Dedicated ultrasound device (Harbin Institute of Technology, Harbin, China) | Noninvasive; biomechanical | Frequency: 1 MHz Intensity: Individually calculated | Atorvastatin and sonodynamic therapy decreased diameter stenosis in PAD lesions after 4 weeks |
| Sonos 5500 (Philips, Bothell, WA) | Noninvasive; biomechanical | Frequency: 1.3 MHz | In healthy subjects, continuous ultrasound did not affect perfusion in limbs, but ultrasound + microbubble cavitation produced a 2.5-fold increase in perfusion. In PAD patients, ultrasound and microbubble cavitation increased perfusion by 2-fold. |
| CardioProlific Genesis System (CardioProlific, Hayward, CA) | Invasive; biomechanical | Frequency: 20 kHz | Treatment group had improved primary patency rates at 6 and 12 months |
| 500M Transcranial Doppler System (Multigon, Elmsford, NY); MultiDop-T (DWL, Singel, Germany) | Noninvasive; biomechanical | Frequency: 2 MHz Intensity: 100% (Multigon); ±128 mW (MultiDop-T) | Complete recanalization was achieved in 36% of patients; dramatic clinical recovery achieved in 20% of patients |
| ATL Ultramark 9 HDI (Philips, Amsterdam, Netherlands) | Noninvasive; biomechanical | Frequency: 2 MHz Intensity: 415 mW/cm² | Partial recanalization achieved in 5 of 6 patients with ultrasound |
| PMD 100 (Spencer Technologies, Seattle, WA); EZ-Dop (DWL, Singen, Germany); Multi-Dop (DWL, Singen, Germany); Multigon 100M; Nicolet Companion III | Noninvasive; biomechanical | Frequency: 2 MHz Intensity: 750 mW (maximum) | Ultrasound and tPA administration resulted in complete recanalization or dramatic clinical recovery from acute ischemic stroke (49% vs 30%; P = .03) |
| TCD 100M (Spencer Technologies, Seattle, WA) | Noninvasive; biomechanical | Frequency: 2 MHz Intensity: 385 mW/cm² | Type of microbubbles did not affect recanalization rates, clinical improvement, bleeding, in-hospital mortality, or long-term outcome |
| Dedicated cervical orthotic device (Luoyang Kangli Medical Instrument Co, Luoyang, China, patent ZL 2012 2 0244630.X) | Noninvasive; biomechanical | Frequency: 800 KHz Intensity: 0.75-1 W/cm² | Decreased thickness and area of carotid plaques (79.94% vs 18.52%) in the ultrasound group |
neointimal hyperplasia without impacting re-endothelialization. In hindlimb ischemic models, HIFU upregulates angiogenic factors and antiapoptotic factors, thus promoting angiogenesis. These effects are potentially mediated by a PI3K-Akt-eNOS pathway. In addition, the angiogenic potential is more dramatic with increasing HIFU line density. HIFU also potentiates thrombolysis, both in conjunction with pharmacologic agents and as a stand-alone modality. Based on the frequency and intensity of HIFU, thrombolytic or thrombotic effects are seen, with the latter potentiating platelet activation through inertial cavitation. However, the precise HIFU settings required to counter-balance these two effects remain unclear. Importantly, while the application of HIFU for hemorrhage control is feasible in animal models, long-term molecular effects on endothelial cell homeostasis is not clearly known.

**Human clinical studies**

The cardiovascular application of HIFU in humans was implemented initially in the treatment of acute stroke for augmenting thrombolysis. Based on the promising preclinical data, the applications of HIFU have also been attempted in carotid artery disease for reduction of plaque burden and in peripheral atherosclerotic disease to evaluate limb perfusion, and the degree of stenosis (Table II). The landmark Combined Lysis of Thrombus with Ultrasound and Systemic tPA for acute ischemic stroke (CLOTBUST) trial assessed the effects of sonothrombolysis, whereby patients with ischemic stroke to the middle cerebral artery were treated with transcranial ultrasound (delivered via a 2-MHz transducer) in addition to intravenous tPA (treatment group, 63 patients; control group, 63 patients).66 The mechanisms behind sonothrombolysis is presumably multifold, and include effects owing to improved drug delivery, thermal and mechanical effects, and molecular changes owing to sonography.19,35,68,69 Patients in the treatment group achieved higher rates of recanalization or dramatic clinical recovery within 2 hours compared with those in the control group (49.0% vs 30%; P < .05). Further subgroup analysis supported long-term functional outcomes at 90 days among those with severe ischemic stroke with National Institutes of Health Stroke Scale scores of 10 or more points treated with sonothrombolysis, in this cohort.70 The Combined Lysis of Thrombus with Ultrasound and Systemic tPA for Emergent Revascularization of acute ischemic stroke (CLOTBUST-ER) trial, implemented a novel operator-independent therapeutic device capable of 2 MHz ultrasound (intensity = 207 mW/cm², pulse repetition frequency 8 × 3 kHz). This trial did not show significant clinical benefits among those treated with ultrasound (n = 317 patients) compared with those treated with standard stroke protocol (n = 329 patients) and was halted early.70-72 However, preliminary findings corroborated the safety features of sonothrombolysis found in previous CLOTBUST trials and analyses, and the study design using this novel device has since been reassessed to use vascular imaging for assessing pretreatment baseline, instead of clinical stroke severity.68,72

The applications of HIFU have also expanded to treating atherosclerosis of the lower extremities. Early clinical experience with this technology has been reported in 1990s. Siegel et al77 reported results of percutaneous peripheral ultrasound angioplasty. In that study, intravascularly applied ultrasound was successful in 86% of patients and resulted in luminal stenosis reduction. In 2016, Gandini et al74 conducted Ultrasound to Enhance Paclitaxel Uptake in Critical Limb Ischemia (PACUS) randomized trial in 56 patients (28 in the control group, 28 in the study group) using the CardioProlific Genesis System (CardioProlific, Hayward, CA) to assess ultrasound energy in conjunction with paclitaxel delivery for treatment of chronic limb-threatening ischemia of femoral popliteal segment.74 The treatment group reported no adverse effects related to the procedure at all follow-up points (6 and 12 months). Angiography demonstrated a higher patency rate among the study group compared with the control group at 6 months of follow-up (96.4% vs 78.5%; P = .04) as well as 12 months of follow-up (96.2% vs 68%; P = .008). This study was followed by the ongoing Ultrasound Plasty to Improve Outcome of Percutaneous Angioplasty in Below-the-Knee Lesions (ULYSSE) trial, which has so far suggested effectiveness of high-intensity ultrasonography preceding angioplasty among patients undergoing below-the-knee angioplasty.78 Also recently, Mason et al33 demonstrated that 1.3 MHz ultrasound exposure using the Sonos 550 (Philips Ultrasound) could increase perfusion among human subjects with PAD, assessed via cavitation of perflutren lipid microbubbles, offering another mechanism by which ultrasound may be used for PAD treatment.33 In addition to lower extremity treatment, HIFU has further been shown to effectively treat carotid atherosclerosis. In a single center, prospective, nonrandomized cohort of 309 carotid plaques treated with ultrasonography using an LHZ.B-100 ultrasound therapy device (intensity = 0.75 to 1 W/cm², frequency = 800 KHz, pulse repetition of 1 H/0.5 seconds), 247 plaques demonstrated decreases in plaque thickness and area compared with those treated with standard medical treatment over 30 days (P < .0001). In this study, the plaque area was evaluated by ultrasound only and the ultrasound technicians were blinded to the treatment groups. Despite this, the study is limited by its design and the potential for interobserver bias. Concordant with other literature, the authors suggested that these results were due to the mechanical effects of ultrasound, cavitation-induced molecular changes, and increased uptake of thrombolytics.77

In summary, the outcomes from various clinical studies have demonstrated positive outcomes with adjunctive
HIFU for arterial recanalization after thrombotic stroke, decreased atherosclerotic plaque burden in carotid arteries, a decrease in diameter stenosis in patients with PAD and increase in tissue perfusion. These current studies serve as a foundation to further optimize HIFU therapy by refining settings (frequency, intensity and treatment duration) to achieve more precise focusing and target lesion effect. Better designed probes with closed-loop real-time feedback systems could optimize therapy for various applications in arterial disease. Although these data are currently limited by their small sample sizes and, single-center or nonrandomized studies and the lack of multicenter randomized trials, they are promising to warrant investigation at a larger scale.

Limitations of HIFU

Although HIFU has been successfully incorporated into clinical practice, there are several factors limiting the widespread incorporation of this technology. Importantly, artifacts inherent to use of diagnostic ultrasound technology are applicable to HIFU as well. Factors such as acoustic shadowing or reverberation by gas or bony structures contribute to inability to penetrate these tissues, particularly for intrabdominal tissue such as the aorta or the iliac arteries.21 Because these ultrasound waves would be reflected toward the HIFU transducer, there is a high likelihood of soft tissue injury or burns. Next, the exact HIFU settings required for thrombolytic versus hemorrhage control applications remain unclear. Importantly, long-term molecular effects on vessel endothelial cell homeostasis from HIFU is not clearly known. Next, the ability to adequately image, focus, target, and monitor tissues with real-time imaging is a significant limitation of currently available HIFU devices. Importantly, although there is a robust body of evidence supporting HIFU in atherosclerotic arterial disease, data supporting the use of HIFU in specific settings correlating to an outcome benefit are lacking. In current iterations, this has been circumvented by using DMUA ultrasound probes or the aid of magnetic resonance imaging (MRgFUS). The use of MRgFUS provides the added benefit of real-time temperature monitoring as well, at a higher cost and being resource intensive. In contrast, although ultrasound-guided monitoring is less resource intensive and has shorter treatment times, reliable tissue temperature monitoring is not available. Multiple efforts to develop sonographic probes capable of temperature monitoring with closed-loop feedback system are underway.79-81 Next, device size remains a limitation with the majority of FDA-approved HIFU devices. The Exablate systems (Tirat Carmel, Israel) are based on HIFU focused by magnetic resonance imaging, requiring dedicated suites to accommodate the HIFU equipment. Similarly, the Ablatherm system (EDAP TMS, Lyon, France) and the Sonablate system (SonaCare Medical, Charlotte, NC) comprise a large treatment and control module that are difficult to transport. In addition, the probe requires constant cooling with degassed water that makes it cumbersome to use for arterial application. Last, as pertaining to arterial disease, the current evidence and heterogeneity of clinical data, the ideal configurations, and settings of HIFU devices are not established. Importantly, there is a paucity of consistent methodology for assessing and grading the histologic, radiographic and clinical effects of HIFU.50 Future research is needed to consolidate device parameters, as well as outcomes.

CONCLUSIONS

HIFU is an established and exciting noninvasive therapeutic modality with a potential to revolutionize the treatment of atherosclerotic arterial disease. HIFU shows great promise in decreasing the progression of atherosclerotic plaque and stabilizing the plaque. As an adjunct to medical therapy, HIFU could be applied to various arterial beds to aid in decreasing plaque thickness and increasing vessel lumen, without the potential issues of neointimal hyperplasia plaging current endovascular therapeutics. Future focused studies are warranted to guide the refinement of HIFU settings and provide capability to precisely focus HIFU with image guidance to safely achieve the desired biologic effect.

AUTHOR CONTRIBUTIONS

Conception and design: AB, SMC, EA
Analysis and interpretation: AB, SMC, AD, NN, EA
Data collection: AB, SMC, EA
Writing the article: AB, SMC, EA
Critical revision of the article: AB, SMC, AD, NN, EA
Final approval of the article: AB, SMC, AD, NN, EA
Statistical analysis: Not applicable
Obtained funding: Not applicable
Overall responsibility: EA
AB and SMC contributed equally to this article and share co-first authorship.

REFERENCES

1. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013;382:1529-40.
2. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015;116:1509-26.
3. Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, Mills JL, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication. J Vasc Surg 2015;61:21S-41S.e1.
4. Hirsch AT, Hartman L, Town R2, Vining BA. National health care costs of peripheral arterial disease in the Medicare population. Vasc Med 2008;13:213-18.
5. Abu Dabrh AM, Steffen MW, Undavalli C, Asl N, Wang Z, Elamin MB, et al. The natural history of untreated severe or critical limb ischemia. Maryland Heights, MO: Mosby Inc.; 2015.p. 152-158.3.
6. Farber A, Eberhardt RT. The current state of critical limb ischemia: a systematic review. Chicago: American Medical Association; 2016. p. 157-60.
7. Fereydooni A, Gorecka J, Dardik A. Using the epidemiology of critical limb ischemia to estimate the number of patients amenable to endovascular therapy. Newbury Park, CA: Sage Publications Ltd. 2020. p. 78-87.
32. Theraclon. FDA approves the 1st trial with Theraclon’s vein therapy in the US. Available at: www.theraclon.com/wp-content/uploads/2021/09/ENG-SEPT-2021_PR_US_SONOVEIN_Final.pdf. 2021. Accessed May, 2022.

33. Steffen W, Fishbein MC, Luo H, Lee DY, Nita H, Cumberland DC, et al. High intensity, low frequency catheter-delivered ultrasound disolution of occlusive coronary artery thrombi: an in vivo and in vitro study. J Am Coll Cardiol 1994;24:1557-9.

34. Steffen W, Cumberland D, Caines P, Luo H, Nita H, Maurer G, et al. Catheter-delivered high intensity, low frequency ultrasound induces vasodilation in vivo. Eur Heart J 1994;15:369-76.

35. Rosenschein U, Bernstein JJ, DiSegni E, Kaplinsky E, Bernheim J, Rozenzsain LA. Experimental ultrasonic angioplasty: disruption of atherosclerotic plaques and thrombi in vivo. J Vasc Interv Radiol. 2004;15:711-7.

36. Francis CW, Blinc A, Lee S, Cox C. Ultrasound accelerates transport of recombinant tissue plasminogen activator into clots. Ultrasound Med Biol 1995;21:419-24.

37. Piazza G, Hohlfelder B, Jaff MR, Ouniel K, Engelhardt TC, Sterling KM, et al. A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II Study. JACC Cardiovasc Interv 2015;8:1382-92.

38. Kucher N, Boekstegers P, Muller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T, et al. Randomized, controlled trial of ultrasound-assisted cather-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014;129:479-88.

39. Raabe RO. Ultrasound-activated thrombolysis in arterial and venous peripheral occlusions: fibrinogen level effects. J Vasc Interv Radiol 2010;21:165-72.

40. Kim YS, Rhim H, Choi MJ, Lim HK, Choi D. High-intensity focused ultrasound therapy: an overview for radiologists. Korean J Radiol 2008;9:291-302.

41. Brodmann M, Werner M, Holden A, Tepe C, Scheinert D, Schwindt A, et al. Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: results of Disrupt PAD II. Catheter Cardiovasc Interv 2019;95:335-42.

42. Brodmann M, Werner M, Brinton TJ, Illindala U, Lansky A, Jaff MR, et al. Safety and performance of lithoplasty for treatment of calcified peripheral artery lesions. J Am Coll Cardiol 2017;70:908-10.

43. Adams G, Shammas N, Mangalmurti S, Bernardo NL, Miller WE, Soukas PA, et al. Intravascular lithotripsy for treatment of calcified lower extremity arterial stenosis: initial analysis of the Disrupt PAD III Study. J Endovasc Ther 2020;27:475-80.

44. Raaz A, Harwood A, Totty J, Smith G, Chetter I. Extracorporeal shockwave therapy for peripheral arterial disease: a review of the current evidence. European J Vasc Endovasc Surg 2017;54:295-8.

45. Holfeld J, Tepekoylu C, Blunder S, Loberwein D, Kirchmair E, Dietl M, et al. Low energy shock wave therapy induces angiogenesis in acute hind-limb ischemia via VEGF receptor 2 phosphorylation. PLoS One 2014;9:e103582.

46. Tepekoylu C, Wang FS, Kozaryn R, Albrecht-Schgoer K, Theurl M, Schaden W, et al. Shock wave treatment induces angiogenesis and mobilizes endogenous CD31/CD34-positive endothelial cells in a hindlimb ischemia model: implications for angiogenesis and vasculogenesis. J Thorac Cardiovasc Surg 2013;146:971-8.

47. Tara S, Miyamoto M, Takagi G, Kimikori-Ichikawa S, Tsuchiya A, Hada T, et al. Low-energy extracorporeal shock wave therapy improves microcirculation blood flow of ischemic limbs in patients with peripheral arterial disease: pilot study. J Nippon Med Sch 2014;81:19-27.

48. Serizawa F, Ito K, Kawamura K, Tsuchida K, Hamada Y, Zukeran T, et al. Extracorporeal shock wave therapy improves the walking ability of patients with peripheral artery disease and intermittent claudication. Circ J 2012;76:1486-93.

49. Ciccone MM, Notarnicola A, Scocchitano P, Saccara M, Carbonara S, Maiorano M, et al. Shockwave therapy in patients with peripheral arterial disease. Adv Ther 2012;29:698-707.

50. Nazer B, Caghihaie F, Kashima R, Khokhlova T, Perez C, Crum L, et al. Therapeutic ultrasound promotes reperfusion and angiogenesis in a rat model of peripheral arterial disease. Circ J 2015;79:2043-9.

51. Lu Z-Y, Li R-L, Zhou H-S, Huang J-J, Su Z-X, Qi J, et al. Therapeutic ultrasound reverses peripheral ischemia in type 2 diabetic mice through P13K-Akt-eNOS pathway. Am J Transl Res 2016;8:3666-77.
52. Wang Y, Wang W, Xu H, Sun Y, Sun J, Jiang Y, et al. Non-lethal sonodynamic therapy inhibits atherosclerotic plaque progression in ApoE-/ mice and attenuates ox-LDL-mediated macrophage impairment by inducing heme oxygenase-1. Cell Physiol Biochem 2017;41:2432-46.

53. Sun X, Guo S, Yao J, Wang H, Peng C, Li B, et al. Rapid inhibition of atherosclerotic plaque progression by sonodynamic therapy. Cardiovasc Res 2019;115:190-203.

54. Groen MHA, Sliker FJB, Vink A, de Borst CJ, Simons MV, Ebbini ES, et al. Safety and feasibility of arterial wall targeting with robot-assisted high intensity focused ultrasound: a preclinical study. Int J Hyperthermia 2020;37:903-12.

55. Mason NR, Davidson BP, Sheeran P, Muller M, Hodovan JM, Sutton J, et al. Augmentation of tissue perfusion in patients with peripheral artery disease using microbubble cavitation. JACC Cardiovasc Imaging 2020;13:641-51.

56. Yao J, Zhao X, Tan F, Cao X, Guo S, Li X, et al. Early modulation of macrophage ROS-PPARγ-NF-κB signalling by sonodynamic therapy attenuates neointimal hyperplasia in rabbits. Sci Rep 2020;10:11638.

57. Poliachik SL, Chandler WL, Mourad PD, Bailey MR, Bloch S, Cleveland RO, et al. Effect of high-intensity focused ultrasound on whole blood with and without microbubble contrast agent. Ultrasound Med Biol 1999;25:991-8.

58. Birnbaum Y. Augmentation of ultrasound-induced clot disruption by nongas-filled microparticles. Echocardiography 2001;18:265-8.

59. Hölscher T, Fisher DJ, Ahadi G, Voie A. Introduction of a rabbit carotid artery model for sonothrombolysis research. Transl Stroke Res 2012;3:397-407.

60. Wright C, Hynynen K, Goertz D. In vitro and in vivo high-intensity focused ultrasound thrombolysis. Invest Radiol 2012;47:217-25.

61. Damianou C, Hadjisavvas V, Mylonas N, Couppis A, Ioannides K. MRI-guided sonothrombolysis of rabbit carotid artery clot. J Stroke Cerebrovasc Dis 2014;23:e113-21.

62. Williams AR, Chater BV, Allen KA, Sherwood MR, Sanderson JH. Release of β-thromboglobulin from human platelets by therapeutic intensities of ultrasound. Br J Haematol 1976;40:133-42.

63. Vaezy S, Martin R, Kaczkowski P, Keilman G, Goldman B, Yaziji H, et al. Use of high-intensity focused ultrasound to control bleeding. J Vasc Surg 1999;29:533-42.

64. Zderic V, Brayman AA, Sharar SR, Crum LA, Vaezy S. Microbubble-enhanced hemorrhage control using high intensity focused ultrasound. Ultrasونics 2006;45:113-20.

65. Lei W, Hu J, Liu Y, Liu W, Chen X. Numerical evaluation of high-intensity focused ultrasound- induced thermal lesions in atherosclerotic plaques. Math Biosci Eng 2021;18:1154-68.

66. Chater BV, Williams AR. Platelet aggregation induced in vitro by therapeutic ultrasound. Thrombos Haemostas 1977;38:640-51.

67. Zderic V, Brayman AA, Sharar SR, Crum LA, Vaezy S. Microbubble-enhanced hemorrhage control using high intensity focused ultrasound. Ultrasونics 2006;45:113-20.